Ycanth
-
West Chester’s Verrica Pharmaceuticals Doubles Ycanth Revenue After Sales Strategy Shift
After overhauling its sales strategy, West Chester-based Verrica Pharmaceuticals more than doubled revenues from Ycanth, its flagship treatment for skin diseases, compared with last year, writes John George for…
-
With New $50 Million Infusion, West Chester’s Verrica Pharmaceuticals to Retire Debt
West Chester-based Verrica Pharmaceuticals has secured $50 million from a private stock sale, which will allow the company to retire its $35 million OrbiMed debt and finance future business activities,…
-
West Chester-Based Verrica Gets Medication Approval in Japan, Triggering $10M Milestone Payment
The regulatory approval of Verrica Pharmaceuticals‘ Ycanth in Japan has triggered a $10 million milestone payment to the West Chester-based company by its overseas partner,…
-
West Chester-based Verrica Pharmaceuticals Agreement Has Potential for $18 Million Boost
West Chester-based Verrica Pharmaceuticals has amended its licensing agreement with Torii Pharmaceutical of Japan, potentially resulting in an $18 million boost in 2025, writes John…
-
West Chester-based Verrica Pharmaceuticals Expects to Raise $42 Million in Public Stock Offering
West Chester-based Verrica Pharmaceuticals expects to raise $42 million in a public stock offering, following staff reductions and the appointment of a new CEO, writes…
-
West Chester-Based Verrica Finally Gets Approval for Skin Disease Treatment
A West Chester pharmaceutical company finally achieved federal approval of a new drug candidate that treats a contagious skin disease, writes John George for the…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
